Eli Lilly and Incyte have announced the results of a Phase 3 COV-BARRIER clinical trial of the jointly developed coronavirus drug baricitinib. The primary endpoint was not reached. The drug reduced the risk of needing ventilation by only 2.7%, which is not statistically significant. However, it did reduce mortality by 38%, which is higher than the recommended standard of care.